Individuals charts and additional tests for changes in spread

Some authors recommend the use of an additional test for detecting increases in the spread, when using a control chart for individual observations. We examine this recommendation both in a practical situation and theoretically. Both studies show that the additional test gives somewhat more power for detecting a 25% increase of the process variation. For nearly all other deviations from the in-control state the test is more likely to cause confusion. From a practical viewpoint we therefore advise against its use.

Isolated eyelid closure myotonia in two families with sodium channel myotonia

Sodium channelopathies (NaCh), as part of the non-dystrophic myotonic syndromes (NDMs), reflect a heterogeneous group of clinical phenotypes accompanied by a generalized myotonia. Because of recent availability of diagnostic genetic testing in NDM, there is a need for identification of clear clinical genotype–phenotype correlations. This will enable clinicians to distinguish NDMs from myotonic dystrophy, thus allowing them to inform patients promptly about the disease, perform genetic counseling, and orient therapy (Vicart et al. Neurol Sci 26:194–202, 2005). We describe the first distinctive clinical genotype–phenotype correlation within NaCh: a strictly isolated eyelid closure myotonia associated with the L250P mutation in SCN4A. Using clinical assessment and needle EMG, we identified this genotype–phenotype correlation in six L250P patients from one NaCh family and confirmed this finding in another, unrelated NaCh family with three L250P patients

Differences in demographic traits of four butterflyfish species between two reefs of the Great Barrier Reef separated by 1,200 km

Author Posting. © The Author(s), 2011. This is the author's version of the work. It is posted here by permission of Springer for personal use, not for redistribution. The definitive version was published in Coral Reefs 31 (2012): 169-177, doi:10.1007/s00338-011-0838-z.Many species demonstrate variation in life history attributes in response to gradients in environmental conditions. For fishes, major drivers of life history variation are changes in temperature and food availability. This study examined large-scale variation in the demography of four species of butterflyfishes (Chaetodon citrinellus, C. lunulatus, C. melannotus, and C. trifascialis) between two locations on Australia’s Great Barrier Reef (Lizard Island and One Tree Island, separated by approximately 1200km). Variation in age-based demographic parameters was assessed using the re-parameterised von Bertalanffy growth function. All species displayed measurable differences in body size between locations, with individuals achieving a larger adult size at the higher latitude site (One Tree Island) for three of the four species examined. Resources and abundances of the study species were also measured, revealing some significant differences between locations. For example, for C. trifascialis, there was no difference in its preferred resource or in abundance between locations, yet it achieved a larger body size at the higher latitude location, suggesting a response to temperature. For some species, resources and abundances did vary between locations, limiting the ability to distinguish between a demographic response to temperature as opposed to a response to food or competition. Future studies of life histories and demographics at large spatial scales will need to consider the potentially confounding roles of temperature, resource usage and availability, and abundance / competition in order to disentangle the effects of these environmental variables.This work was supported by a National Science Foundation (USA) Graduate Research Fellowship (MLB) and by PADI Project A.W.A.R.E. (MLB).2012-11-1

Studying the evolution of software systems using change clusters

Thirteenth International Symposium on Temporal Representation and Reasoning, TIME 2006, Athens, Greece.In this paper, we present an approach that examines the evolution of code stored in source control repositories. The technique identifies Change Clusters which can help managers to classify different code change activities as software maintenance or new development. Furthermore, identifying the variations in Change Clusters over time exposes trends in the development of a software system. We present a case study, which uses a sequence of Change Clusters to track the evolution of the PostgreSQL software project. Our case study demonstrates that our technique reveals interesting patterns about the progress of code development within each release of PostgreSQL. We show that the increase in the number of clusters not only identifies the areas where development has occurred, but reflects the magnitude of change in code. We also compare how the Change Clusters vary over time in order to make generalizations about the focus of development

Male-Specific Association between a γ-Secretase Polymorphism and Premature Coronary Atherosclerosis

Contains fulltext : 69125.pdf (publisher's version ) (Open Access)6 p

Association Between Increased Platelet P-Selectin Expression and Obesity in Patients With Type 2 Diabetes: A BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy

OBJECTIVE- To determine whether obesity increases platelet reactivity and thrombin activity in patients with type 2 diabetes plus stable coronary artery disease. RESEARCH DESIGN AND METHODS- We assessed platelet reactivity and markers of thrombin generation and activity in 193 patients from nine clinical sites of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). Blood taken at the time of enrollment was used for assay of the concentration of prothrombin fragment 1.2 (PT1.2, released when prothrombin is activated) and fibrinopeptide A (FPA, released when fibrinogen is cleaved). Platelet activation was identified with the use of flow cytometry in response to 0, 0.2, and 1 mu mol/l adenosine diphosphate (ADP). RESULTS- Concentrations of FPA, PT1.2, and platelet activation in the absence of agonist were low. Greater BMI was associated with higher platelet reactivity in response to 1 mu m ADP as assessed by surface expression of P-selectin (r = 0.29, P < 0.0001) but not reflected by the binding of fibrinogen to activated glycoprotein IIb-IIIa. BMI was not associated with concentrations of FPA or PT1.2. Platelet reactivity correlated negatively with A1C (P < 0.04), was not related to the concentration Of triglycerides in blood, and did not correlate with the concentration of C-reactive peptide. CONCLUSIONS- Among patients enrolled in this substudy of BARI 2D, a greater BMI was associated with higher platelet reactivity at the time of enrollment. Our results suggest that obesity and insulin resistance that accompanies obesity may influence platelet reactivity in patients with type 2 diabetes.National Heart, Lung, and Blood Institute (NHLBI/NIH)[R01 HL69146]National Heart, Lung, and Blood Institute (NHLBI/NIH)[R01 HL71306]NHLBI[U01 HL061746]NHLBI[U01 HL06171748]NHLBI[U01 HL06384]National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK/NIH)[HL061744

Platelets in Patients with Premature Coronary Artery Disease Exhibit Upregulation of miRNA340* and miRNA624*

Coronary artery disease (CAD) is the leading cause of human morbidity and mortality worldwide, underscoring the need to improve diagnostic strategies. Platelets play a major role, not only in the process of acute thrombosis during plaque rupture, but also in the formation of atherosclerosis itself. MicroRNAs are endogenous small non-coding RNAs that control gene expression and are expressed in a tissue and disease-specific manner. Therefore they have been proposed to be useful biomarkers. It remains unknown whether differences in miRNA expression levels in platelets can be found between patients with premature CAD and healthy controls. In this case-control study we measured relative expression levels of platelet miRNAs using microarrays from 12 patients with premature CAD and 12 age- and sex-matched healthy controls. Six platelet microRNAs were significantly upregulated (miR340*, miR451, miR454*, miR545:9.1. miR615-5p and miR624*) and one miRNA (miR1280) was significantly downregulated in patients with CAD as compared to healthy controls. To validate these results, we measured the expression levels of these candidate miRNAs by qRT-PCR in platelets of individuals from two independent cohorts; validation cohort I consisted of 40 patients with premature CAD and 40 healthy controls and validation cohort II consisted of 27 patients with artery disease and 40 healthy relatives. MiR340* and miR624* were confirmed to be upregulated in patients with CAD as compared to healthy controls in both validation cohorts. Two miRNAs in platelets are significantly upregulated in patients with CAD as compared to healthy controls. Whether the two identified miRNAs can be used as biomarkers and whether they are cause or consequence of the disease remains to be elucidated in a larger prospective stud

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

IMPORTANCE: Secretory phospholipase A2(sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. OBJECTIVE: To determine the effects of sPLA2inhibition with varespladib on cardiovascular outcomes. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). INTERVENTIONS: Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. MAIN OUTCOMES AND MEASURES: The primary efficacy measurewas a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. RESULTS: At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95%CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95%CI, 1.16-2.39; log-rank P = .005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). CONCLUSIONS AND RELEVANCE: In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130246. Copyright 2014 American Medical Association. All rights reserved